What the "90% cheaper" headline actually means
Start with the caveat. "Ninety per cent cheaper" is not a measured average of like-for-like care. It is drawn from selected comparisons: cash prices at large Chinese public hospitals, set against US billed charges before any insurer discount. Both sides are chosen, and both flatter the conclusion.
US billed charges are not what insurers or Medicare usually pay; negotiated rates are typically lower. Chinese quotations often cover the surgical episode and a standard ward bed, not the Western package of workup, rehabilitation and follow-up. Compare like with like and the gap narrows.
A more honest statement: for many common operations paid in cash at a large Chinese public hospital, the bill can be a small fraction of the US cash price — a range from roughly half to about a tenth, depending on the procedure and what is included. Any single percentage across all of medicine averages things that should not be averaged.
A price describes a payment system. It does not describe the medicine.
This is cost journalism, not medical advice, not a recommendation of any hospital, and not a prediction of your bill.
The structural reasons prices differ
The gap comes from five structural features of Chinese healthcare, not from hospitals being cleverer.
A national fee schedule for procedures
China regulates the price of medical services. Provincial authorities publish fee schedules setting ceilings for defined procedures, examinations and bed days. A surgeon does not set a market price for an appendicectomy; the schedule does. That price reflects policy decisions about affordability, not what buyers might bear.
Centralised volume-based procurement
The second driver is centralised volume-based procurement, run under China's National Healthcare Security Administration and usually shortened to VBP. The state aggregates hospital demand and tenders it as one guaranteed volume. Manufacturers bid, and distributors lose the margin they earned on every unit.
It began with medicines around 2019 and was extended to high-value consumables including cardiac stents and orthopaedic implants. In the first national procurement for coronary stents, reported around late 2020, winning prices fell to roughly a tenth of their previous level, and hip and knee implants followed into comparable procurement. These are device prices, but where the implant dominates the bill, that is the difference.
Labour and facility costs
Clinical labour is cheaper in China than in the United States, and so is the fixed cost of running a building. Salaries for nurses, technicians and junior doctors sit at a fraction of US levels, and construction, utilities and back-office staffing cost less. Hospital care is labour-intensive, so a lower wage base feeds into the price of care.
No US-style administrative-billing layer
US hospital bills are produced inside an apparatus built to price, code, submit, deny, appeal and reconcile claims, absorbing a substantial share of US health spending. Chinese public hospitals bill one dominant public payer, with standardised fee items and far less negotiation per claim.
Much lower malpractice-insurance costs
US physicians in high-risk specialties pay malpractice premiums that can reach tens or hundreds of thousands of dollars a year, with hospital liability costs on top. Litigation is less frequent and awards lower in China. That is a genuine structural difference, and also a difference in how patients are compensated when things go wrong.
Where each part of a bill comes from
The table breaks a single operation — a primary total knee replacement without complications — into components. The figures vary by hospital and year; what matters is why each component behaves as it does.
| Cost component | Main driver in the US | Main driver in China | Structural reason for the gap |
|---|---|---|---|
| Implant | Manufacturer list price negotiated by purchasing groups | National tendered price after volume-based procurement | Aggregated state purchasing removes distributor margin |
| Surgeon and anaesthesia fees | Specialty market rates and fee-for-service coding | Government fee schedule ceilings | Professional prices are administered, not negotiated per case |
| Ward bed and nursing | High clinical wage base, per-day charges | Lower wage base, regulated bed-day rates | Labour and facility costs differ several-fold |
| Imaging and labs | Facility fee plus professional fee | Schedule price per item | Each item is priced administratively |
| Medication | Brand pricing and pharmacy mark-up | Generics plus centralised procurement | Tendered generics and reduced mark-up |
| Billing and administration | Coders, billers, denials, prior authorisation | Standard items to one dominant public payer | An entire revenue-cycle layer is largely absent |
| Liability and insurance | Malpractice premiums and hospital liability cover | Lower litigation frequency and awards | Legal risk is priced far lower |
What is not cheaper
The gap is not uniform, and patients who budget from the headline get surprised.
- Imported patented drugs. A brand-name medicine still under patent tends to carry the manufacturer's international price. Procurement has pushed hard on generics and off-patent products, not on patented imports.
- Some biologics and targeted cancer therapies. Several have been negotiated into the national reimbursement list at reduced prices, but those outside it remain expensive, and the newest agents may be priced near international levels.
- Premium private rooms and international departments. A single room in an international wing, with English-speaking staff and hotel-style service, approaches Western private rates.
- Imported implants at list price. If a surgeon uses a device outside the procured range — a premium brand or a newer design — the saving on that line shrinks or disappears.
Why price is not quality
A lower price is not evidence of worse surgery, just as a higher one is not evidence of better surgery. The US price level reflects a wage structure, an insurance architecture and a liability market, not a certificate of quality.
The difference is not meaningless, though. At the top tier of Chinese hospitals, in high-volume departments, reported outcomes for common major procedures are broadly comparable to international benchmarks. Where a gap tends to be real is elsewhere: in the long tail of lower-tier hospitals, in multidisciplinary care for advanced cancer, in access to the newest drugs and devices, and in the wrap-around services — rehabilitation, discharge planning, follow-up — that Western systems deliver unevenly but deliver more of. A lower price can reflect a thinner service rather than a more efficient one.
What this means in practice for a self-paying patient
If you are paying yourself, the headline saving is real but it is not the whole budget. Build your estimate from an itemised quote covering the implant by name, ward class, intensive care if needed, medication, imaging and a contingency for complications. Then add what the bill will not include: flights, accommodation for a companion, an interpreter, a visa, travel insurance, and the possibility of a longer stay.
Then ask what the price does not buy. A cash price at a large public hospital usually buys the surgical episode, not months of rehabilitation, coordination between departments, or the certainty that someone at home will own your recovery at week six.
None of this is medical advice. It is an attempt to explain where the numbers come from.
References
- National Healthcare Security Administration of China — centralised volume-based procurement
- BMJ Global Health — Improving access to medicines and beyond: the national volume-based procurement policy in China
- National Health Commission of the People's Republic of China — official English portal
- World Health Organization — Medicines
- World Health Organization — Health financing
- World Health Organization — Model lists of essential medicines
- National Institute for Health and Care Excellence — Health technology evaluations: the manual